Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting

10/9/24 7:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MRNS alert in real time by email

Includes additional data from the Phase 3 RAISE trial in refractory status epilepticus (SE) and data from a retrospective claims-based analysis on the management of SE

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that additional data from the Phase 3 RAISE trial in refractory status epilepticus and retrospective claims-based data from patients with status epilepticus will be presented at the upcoming Neurocritical Care Society (NCS) 22^nd Annual Meeting, being held October 14-17 in San Diego, California.

Presentation details are as follows:

Podium Presentation Details:

Thursday, October 17, 2024, 9:35-9:55 a.m. PT

Title: Efficacy and Safety of Intravenous Ganaxolone for Treatment of Refractory Status Epilepticus: Results from the Phase 3, Double-Blind, Randomized, Placebo-Controlled RAISE Trial
Presenting Author: Brandon Foreman, M.D., M.S., FACNS, FNCS, Associate Professor of Neurology & Rehabilitation Medicine and Neurosurgery at the University of Cincinnati and Associate Director for Neurocritical Care Research
Session: Late-Breaking Science Oral Platform

Poster Presentation Details:

Wednesday, October 16, 2024, 2:45-3:45 p.m. PT

Title: High Rate of Interhospital Transfers in Status Epilepticus: Challenges in Management of Care
Presenting Author: Henrikas Vaitkevicius, M.D., VP, Clinical Development, Marinus Pharmaceuticals
Session: Poster Session Day 2

About Marinus Pharmaceuticals

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company's product, ZTALMY^® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the U.S. in 2022. For more information, please visit www.marinuspharma.com and follow us on Facebook, LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241009774652/en/

Get the next $MRNS alert in real time by email

Recent Analyst Ratings for

$MRNS

Date	Price Target	Rating	Analyst
9/23/2024	$6.00	Perform → Outperform	Oppenheimer
8/14/2024		Buy → Neutral	Ladenburg Thalmann
4/16/2024	$20.00 → $2.00	Outperform → Neutral	Robert W. Baird
4/15/2024	$24.00 → $3.00	Outperform → Sector Perform	RBC Capital Mkts
8/11/2023	$14.00 → $9.00	Outperform → Perform	Oppenheimer
1/20/2023	$23.00	Outperform	RBC Capital Mkts
12/20/2021	$32.00 → $30.00	Outperform	SVB Leerink

More analyst ratings

Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting

Chat with this insight

Recent Analyst Ratings for
$MRNS

$MRNS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Marinus Pharmaceuticals upgraded by Oppenheimer with a new price target

Marinus Pharmaceuticals downgraded by Ladenburg Thalmann

Marinus Pharmaceuticals downgraded by Robert W. Baird with a new price target

$MRNS
SEC Filings

SEC Form 15-12G filed by Marinus Pharmaceuticals Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Marinus Pharmaceuticals Inc.

SEC Form EFFECT filed by Marinus Pharmaceuticals Inc.

$MRNS
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

CHAIRMAN AND CEO Braunstein Scott bought $6,526 worth of shares (5,933 units at $1.10) and returned $167,530 worth of shares to the company (304,600 units at $0.55), closing all direct ownership in the company (SEC Form 4)

$MRNS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Ezickson Elan returned $5,995 worth of shares to the company (10,900 units at $0.55), closing all direct ownership in the company (SEC Form 4)

Director Fischer Seth H. Z. returned $8,254 worth of shares to the company (15,007 units at $0.55), closing all direct ownership in the company (SEC Form 4)

CHIEF MEDICAL OFFICER Hulihan Joseph returned $39,999 worth of shares to the company (72,725 units at $0.55), closing all direct ownership in the company (SEC Form 4)

Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting

Chat with this insight

Recent Analyst Ratings for $MRNS

$MRNS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Marinus Pharmaceuticals upgraded by Oppenheimer with a new price target

Marinus Pharmaceuticals downgraded by Ladenburg Thalmann

Marinus Pharmaceuticals downgraded by Robert W. Baird with a new price target

$MRNS SEC Filings

SEC Form 15-12G filed by Marinus Pharmaceuticals Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Marinus Pharmaceuticals Inc.

SEC Form EFFECT filed by Marinus Pharmaceuticals Inc.

$MRNS Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

CHAIRMAN AND CEO Braunstein Scott bought $6,526 worth of shares (5,933 units at $1.10) and returned $167,530 worth of shares to the company (304,600 units at $0.55), closing all direct ownership in the company (SEC Form 4)

$MRNS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Ezickson Elan returned $5,995 worth of shares to the company (10,900 units at $0.55), closing all direct ownership in the company (SEC Form 4)

Director Fischer Seth H. Z. returned $8,254 worth of shares to the company (15,007 units at $0.55), closing all direct ownership in the company (SEC Form 4)

CHIEF MEDICAL OFFICER Hulihan Joseph returned $39,999 worth of shares to the company (72,725 units at $0.55), closing all direct ownership in the company (SEC Form 4)

Recent Analyst Ratings for
$MRNS

$MRNS
Analyst Ratings

$MRNS
SEC Filings

$MRNS
Insider Purchases

$MRNS
Insider Trading